LQDA, US53635D2027

Liquidia stock trades 67.3 percent below its 52-week high on October 16, 2026

Published on 10/17/2026 at 19:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Liquidia's P/E was 25.09 on October 16, 2026. Liquidia stock costs EUR 30.60 on October 16, 2026, down 1.23 percent versus the Tradegate close.

Valuation and trading position

Liquidia stock stood 67.31 percent below its 52-week high on October 16, 2026.
Liquidia had a P/E ratio of 25.09 and a market capitalization of USD 3.1 billion on October 16, 2026.
Liquidia stock costs EUR 30.60 at Tradegate on October 16, 2026 at 3:00 p.m. CEST, 1.23 percent below the Tradegate close of October 15, 2026.
MarketBeat estimated Liquidia's next quarterly report for November 2, 2026.

LQDA, US53635D2027, Illustration mit AI erstellt.

Liquidia stock stood 67.31 percent below its 52-week high on October 16, 2026, after the latest Tradegate quote reached EUR 30.60. The distance puts the company valuation and upcoming reporting date ahead of the next major data point for investors. Liquidia stock last stood at EUR 30.60 on Tradegate on October 16, 2026 at 3:00 p.m. CEST, down 1.23 percent versus the Tradegate close of October 15, 2026.

The valuation remains measurable

Liquidia had a market capitalization of USD 3.1 billion and a P/E ratio of 25.09 on October 16, 2026. The company operates in healthcare and pharmaceuticals, developing inhaled therapies for pulmonary arterial hypertension and other serious cardiopulmonary diseases.

Its latest reported second-quarter revenue was USD 171.68 million for the period ended June 30, 2026, while diluted earnings per share were USD 0.74. Revenue exceeded the consensus estimate of USD 168.48 million, whereas earnings per share came in below the USD 0.76 consensus estimate, according to MarketBeat.

Range and trading comparison

The 52-week range was USD 21.94 to USD 93.61 on October 16, 2026. The EUR 30.60 Tradegate quote was 39.47 percent above the low and 67.31 percent below the high. The stock's one-year performance was 53.00 percent, according to the dated market overview.

Valuation and the next date

Liquidia's latest quoted valuation was accompanied by a zero dividend yield. MarketBeat estimated the next quarterly report for November 2, 2026, before the market opened. The date remains the next scheduled reference point for the company.

Comparison with peers

LQDA: minus 1.23 percent, P/E 25.09, market capitalization USD 3.1 billion.

United Therapeutics (Nasdaq, USD): minus 1.55 percent, P/E 19.10, market capitalization USD 22.9 billion.

Gossamer Bio (Nasdaq, USD): minus 1.35 percent, P/E minus 0.16, market capitalization USD 53.6 million.

What the next report can add

Liquidia's second-quarter figures give the market a concrete operating benchmark, while the latest valuation remains tied to expectations for its pulmonary hypertension portfolio. The November reporting date should provide the next period-specific update on revenue and earnings.

Trading position stays below the high

Liquidia was last quoted at EUR 30.60 on Tradegate on October 16, 2026 at 3:00 p.m. CEST, 1.23 percent below the Tradegate close of October 15, 2026. The quote was 67.31 percent below the 52-week high of USD 93.61, with the currencies kept separate.